Cargando…

Clinical targeting recombinant immunotoxins for cancer therapy

Recombinant immunotoxins (RITs) are proteins that contain a toxin fused to an antibody or small molecules and are constructed by the genetic engineering technique. RITs can bind to and be internalized by cells and kill cancerous or non-cancerous cells by inhibiting protein synthesis. A wide variety...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Meng, Liu, Zeng-Shan, Liu, Xi-Lin, Hui, Qi, Lu, Shi-Ying, Qu, Lin-Lin, Li, Yan-Song, Zhou, Yu, Ren, Hong-Lin, Hu, Pan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5530862/ https://www.ncbi.nlm.nih.gov/pubmed/28790855 http://dx.doi.org/10.2147/OTT.S134584

Ejemplares similares

Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors
por: Hagerty, Brendan L., et al.
Publicado: (2020)

Construction, Expression, and Characterization of a Recombinant Immunotoxin Targeting EpCAM
por: Lv, Minghua, et al.
Publicado: (2015)

Evaluation of Hydra HALT-1 as a toxin moiety for recombinant immunotoxin
por: Jiemy, William F., et al.
Publicado: (2020)

Recombinant immunotoxins development for HER2-based targeted cancer therapies
por: Mahmoudi, Reza, et al.
Publicado: (2021)

Recombinant Immunotoxin Therapy of Glioblastoma: Smart Design, Key Findings, and Specific Challenges
por: Zhu, Shaowei, et al.
Publicado: (2017)

In vivo solid tumor targeting with recombinant VEGF-diphtheria immunotoxin
por: Hosseininejad-Chafi, Mohammad, et al.
Publicado: (2022)

Antitumor Efficacy of EGFR-Targeted Recombinant Immunotoxin in Human Head and Neck Squamous Cell Carcinoma
por: Xie, Guiqin, et al.
Publicado: (2022)

Strategies to mitigate the on- and off-target toxicities of recombinant immunotoxins: an antibody engineering perspective
por: Li, Mengyu, et al.
Publicado: (2022)

Development of Recombinant Immunotoxins for Hairy Cell Leukemia
por: Kreitman, Robert J., et al.
Publicado: (2020)

Immunotoxin Therapy for Lung Cancer
por: Xie, Li-Yi, et al.
Publicado: (2017)

Hosts for Hostile Protein Production: The Challenge of Recombinant Immunotoxin Expression
por: Zuppone, Stefania, et al.
Publicado: (2019)

Anti-tumor effects of a recombinant anti-prostate specific membrane antigen immunotoxin against prostate cancer cells
por: Meng, Ping, et al.
Publicado: (2017)

Dual B- and T-cell de-immunization of recombinant immunotoxin targeting mesothelin with high cytotoxic activity
por: Mazor, Ronit, et al.
Publicado: (2016)

Recombinant immunotoxin induces tumor intrinsic STING signaling against head and neck squamous cell carcinoma
por: Xie, Guiqin, et al.
Publicado: (2023)

Novel Therapy for Atherosclerosis Using Recombinant Immunotoxin Against Folate Receptor β–Expressing Macrophages
por: Furusho, Yuko, et al.
Publicado: (2012)

A Single-Domain Antibody-Based Anti-PSMA Recombinant Immunotoxin Exhibits Specificity and Efficacy for Prostate Cancer Therapy
por: Xing, Yutong, et al.
Publicado: (2021)

Manufacture and evaluation of a HER2-positive breast cancer immunotoxin 4D5Fv-PE25
por: Peng, Yanjie, et al.
Publicado: (2023)

Interactions Between Pseudomonas Immunotoxins and the Plasma Membrane: Implications for CAT-8015 Immunotoxin Therapy
por: Bokori-Brown, Monika, et al.
Publicado: (2018)

Recombinant immunotoxin targeting GPC3 is cytotoxic to H446 small cell lung cancer cells
por: Rodakowska, Ewelina, et al.
Publicado: (2021)

Recombinant Immunotoxin 4D5scFv-PE40 for Targeted Therapy of HER2-Positive Tumors
por: Sokolova, E. A., et al.
Publicado: (2015)

Recombinant immunotoxins targeting B-cell maturation antigen are cytotoxic to myeloma cell lines and myeloma cells from patients
por: Bera, T K, et al.
Publicado: (2018)

Novel EGFR-bispecific recombinant immunotoxin based on cucurmosin shows potent anti-tumor efficiency in vitro
por: Zhang, Caiyun, et al.
Publicado: (2021)

Evaluating the influence of common antibiotics on the efficacy of a recombinant immunotoxin in tissue culture
por: Zhu, Yuyi, et al.
Publicado: (2019)

Cytotoxins and immunotoxins for cancer therapy : clinical applications /
Publicado: (2005)

Immunotoxins: experimental design
por: Dall, P, et al.
Publicado: (2001)

Immunotoxins: The Role of the Toxin (†)
por: Antignani, Antonella, et al.
Publicado: (2013)

Countering immunotoxin immunogenicity
por: Flavell, David J
Publicado: (2016)

A novel recombinant immunotoxin-based therapy targeting wild-type and mutant EGFR improves survival in murine models of glioblastoma
por: Chandramohan, Vidyalakshmi, et al.
Publicado: (2013)

Abrin Immunotoxin: Targeted Cytotoxicity and Intracellular Trafficking Pathway
por: Gadadhar, Sudarshan, et al.
Publicado: (2013)

Naptumomab Estafenatox: Targeted Immunotherapy with a Novel Immunotoxin
por: Eisen, Tim, et al.
Publicado: (2014)

Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer
por: Fleming, Bryan D., et al.
Publicado: (2016)

A multi-antigen vaccine in combination with an immunotoxin targeting tumor-associated fibroblast for treating murine melanoma
por: Fang, Jinxu, et al.
Publicado: (2016)

Novel CD7-specific nanobody-based immunotoxins potently enhanced apoptosis of CD7-positive malignant cells
por: Tang, Jinle, et al.
Publicado: (2016)

Systemic immunotoxin therapy of cancer: advances and prospects.
por: Wawrzynczak, E. J.
Publicado: (1991)

Antibody-Based Immunotoxins for Colorectal Cancer Therapy
por: Sanz, Laura, et al.
Publicado: (2021)

Treatment of solid tumors with immunotoxins
por: Messmer, Davorka, et al.
Publicado: (2005)

Bouganin, an Attractive Weapon for Immunotoxins
por: Bortolotti, Massimo, et al.
Publicado: (2018)

B7-1 (CD80) as target for immunotoxin therapy for Hodgkin's disease.
por: Vooijs, W. C., et al.
Publicado: (1997)

Targeting malignant B cells with an immunotoxin against ROR1
por: Baskar, Sivasubramanian, et al.
Publicado: (2012)

Targeted Anticancer Immunotoxins and Cytotoxic Agents with Direct Killing Moieties
por: Kawakami, Koji, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_6e7018rlgguaj4aacg559lt6ft